Cell-Based Therapies Program
Critical Limb Ischemia (CLI) is a peripheral artery disease caused due to massive occlusion of blood flow to lower extremities. It is often associated with excruciating pain and lead to the development of skin ulcers or gangrene.
The five-year survival rate of Critical Limb Ischemia patients is 50 percent after initial diagnosis. For patients that fall into the extreme spectrum of Critical Limb Ischemia that cannot tolerate surgical intervention, limb amputation is the only treatment option. Cell-based therapies provide immense hope to promote wound healing and restore blood perfusion in treating Critical Limb Ischemia patients.
In recent clinical trials, Michael P. Murphy, MD and colleagues at Indiana University School of Medicine have successfully achieved blood perfusion restoration using intramuscular injection of endometrial regenerative cells (ERC) (NCT01558908) and autologous bone marrow aspirate (NCT01049919) in Critical Limb Ischemia patients. Based on these advancements, the Center for Regenerative Medicine and Engineering is engaged in collaborative efforts from basic scientists, bioengineers and vascular surgeons to develop novel cell-based therapies for Critical Limb Ischemia and related diseases.
Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH. Allogeneic endometrial regenerative cells: an “Off the shelf solution” for critical limb ischemia?. J Transl Med, 6:45.
Murphy MP1, Lawson JH, Rapp BM, Dalsing MC, Klein J, Wilson MG, Hutchins GD, March KL. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg, 1565-74.